Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.